背景:有充分的证据表明,淀粉样蛋白-β(Aβ)正电子发射断层扫描(PET)信号升高与临床正常(CN)个体的认知能力下降有关。然而,在该人群中,Aβ负担与日常生活活动下降之间是否存在关联尚不明确。此外,尚未建立可以最佳预测功能下降的Aβ-PETCentiloids(CL)阈值。
方法:对欧洲淀粉样蛋白-PET成像AMYPAD-PNHS数据集进行了平均三年时间范围的横截面和纵向分析,该数据集表型为1260名个体,包括1032名CN个人和228名患有可疑功能障碍的参与者。在Centiloid(CL)量表和使用Aβ组(CL<12=Aβ-,12≤CL≤50=Aβ-中间体/Aβ±,CL>50=Aβ+)。使用临床痴呆评级(Global-CDR,CDR-SOB)和阿姆斯特丹日常生活工具活动问卷(A-IADL-Q)。基线时,1260名参与者可获得Global-CDR,而基线CDR-SOB和A-IADL-Q评分和纵向功能数据可用于具有与整个样本相似特征的不同子样本。
结果:参与者包括765Aβ-(61%,Mdnage=66.0,IQRage=61.0-71.0;59%的女性),301个Aβ±(24%;Mdnage=69.0,IQRage=64.0-75.0;53%女性)和194个Aβ个体(15%,Mdnage=73.0,IQRage=68.0-78.0;53%的女性)。跨领域,CL值与CDR结果相关。纵向,基线CL值预测CDR-SOB的预期变化(bCL*时间=0.001/CL/年,95%CI[0.0005,0.0024],p=.003)和A-IADL-Q(bCL*时间=-0.010/CL/年,95%CI[-0.016,-0.004],p=.002)初始CN参与者的分数。主要在Aβ+CN个体中观察到临床进展增加(Global-CDR>0)(HRAβ+vsAβ-=2.55,95%CI[1.16,5.60],p=.020)。使用CDR-SOB在41CL找到了预测下降的最佳阈值(bAβ+vsAβ-=0.137/年,95%CI[0.069,0.206],p<.001)和28CL使用A-IADL-Q(bAβvsAβ-=-0.693/年,95%CI[-1.179,-0.208],p=.005)。
结论:淀粉样蛋白-PET定量支持鉴定有功能减退风险的CN个体。
背景:AMYPADPNHS在www上注册。临床试验登记。欧盟EudraCT编号:2018-002277-22。
BACKGROUND: There is good evidence that elevated amyloid-β (Aβ) positron emission tomography (PET) signal is associated with cognitive decline in clinically normal (CN) individuals. However, it is less well established whether there is an association between the Aβ burden and decline in daily living activities in this population. Moreover, Aβ-PET Centiloids (CL) thresholds that can optimally predict functional decline have not yet been established.
METHODS: Cross-sectional and longitudinal analyses over a mean three-year timeframe were performed on the European amyloid-PET imaging AMYPAD-PNHS dataset that phenotypes 1260 individuals, including 1032 CN individuals and 228 participants with questionable functional impairment. Amyloid-PET was assessed continuously on the Centiloid (CL) scale and using Aβ groups (CL < 12 = Aβ-, 12 ≤ CL ≤ 50 = Aβ-intermediate/Aβ± , CL > 50 = Aβ+). Functional abilities were longitudinally assessed using the Clinical Dementia Rating (Global-CDR, CDR-SOB) and the Amsterdam Instrumental Activities of Daily Living Questionnaire (A-IADL-Q). The Global-CDR was available for the 1260 participants at baseline, while baseline CDR-SOB and A-IADL-Q scores and longitudinal functional data were available for different subsamples that had similar characteristics to those of the entire sample.
RESULTS: Participants included 765 Aβ- (61%, Mdnage = 66.0, IQRage = 61.0-71.0; 59% women), 301 Aβ± (24%; Mdnage = 69.0, IQRage = 64.0-75.0; 53% women) and 194 Aβ+ individuals (15%, Mdnage = 73.0, IQRage = 68.0-78.0; 53% women). Cross-sectionally, CL values were associated with CDR outcomes. Longitudinally, baseline CL values predicted prospective changes in the CDR-SOB (bCL*Time = 0.001/CL/year, 95% CI [0.0005,0.0024], p = .003) and A-IADL-Q (bCL*Time = -0.010/CL/year, 95% CI [-0.016,-0.004], p = .002) scores in initially CN participants. Increased clinical progression (Global-CDR > 0) was mainly observed in Aβ+ CN individuals (HRAβ+ vs Aβ- = 2.55, 95% CI [1.16,5.60], p = .020). Optimal thresholds for predicting decline were found at 41 CL using the CDR-SOB (bAβ+ vs Aβ- = 0.137/year, 95% CI [0.069,0.206], p < .001) and 28 CL using the A-IADL-Q (bAβ+ vs Aβ- = -0.693/year, 95% CI [-1.179,-0.208], p = .005).
CONCLUSIONS: Amyloid-PET quantification supports the identification of CN individuals at risk of functional decline.
BACKGROUND: The AMYPAD PNHS is registered at www.clinicaltrialsregister.eu with the EudraCT Number: 2018-002277-22.